Choosing seafood by species, taste and actual monitoring
In this investigation
My workable preference is small oily fish that I can finish in one sitting and actually enjoy. The sardines were bland for my taste; the anchovies were too salty. That experience calls for a better product choice, rather than a rule that every seafood meal needs to include something unpleasant. The seafood nutrition investigation explains what oily fish and other seafood contribute. Here the question is how to make that choice while reading contaminant evidence accurately.
Species is more informative than the word “fish”
The FDA/EPA chart distinguishes lower-mercury species from king mackerel. Its pregnancy/breastfeeding/child serving schedule is not my adult-male prescription. The seafood comparison gives the species names.
The FDA’s detailed commercial-fish table shows why sardines are a reasonable candidate, while also showing the limitations of a species average:
| Seafood | Historical mean mercury, ppm | Samples | Collection period or source |
|---|---|---|---|
| Sardines | 0.013 | 90 | FDA, 2002–2010 |
| Anchovies | 0.016 | 15 | FDA, 2007–2009 |
| Fresh/frozen salmon | 0.022 | 94 | FDA, 1991–2009 |
| Canned light tuna | 0.126 | 545 | FDA, 1991–2010 |
| Canned albacore tuna | 0.350 | 451 | FDA, 1991–2009 |
These are historical observations, not tests of today’s can. Sardine samples ranged from below detection to 0.083 ppm. Concentration and amount eaten both matter: multiplying the historical mean of 0.013 µg/g by an illustrative 80 g portion gives about 1.0 µg mercury. That arithmetic explains exposure; it does not measure my sardines or set a personal safe limit. FDA commercial-fish monitoring table.
The FDA also lists a 1 ppm methylmercury action level for the edible portion of seafood. This is an enforcement reference, not a recommended daily intake or proof that every amount of a product below it is appropriate for frequent consumption. FDA contaminant transparency tool.
Newer monitoring provides context, not a brand ranking
In January 2026 the FDA released its Total Diet Study interface and the FY2021–FY2022 results. “Released in 2026” does not mean collected in 2026. The dataset includes prepared foods and pooled samples rather than a test of every retail product. Regional results combine foods from three cities; national foods can combine brands or varieties selected to represent substantial market share. 2026 release, sampling design.
Reading the released FY2021–FY2022 elements data gives the following mercury observations:
| Prepared food category | Composite results | Mercury range, ppb |
|---|---|---|
| Salmon, steaks/fillets, baked | 17 | 4.5–32 |
| Shrimp, pre-cooked, shells removed | 17 | 2.9–22.3 |
| Tuna, canned in water, drained solids | 2 | 178–190 |
One thousand ppb equals one ppm. These category results are consistent with the usefulness of species selection, but two pooled tuna results cannot establish every tuna product’s concentration. This dataset has no sardine or anchovy food category, so it cannot replace the older sardine-specific monitoring with a current test of my product. FDA TDS interface, Elements Report.
Low mercury does not describe every contaminant
A concrete example comes from processed clams, which are low-mercury seafood but can have a different source-specific problem. In the FDA’s 2022 targeted seafood survey, some canned clams from China had PFOA exposures judged to be a health concern, leading to recalls. Follow-up sampling from the two implicated processors during 2022–2024 found PFOA in all 12 samples; three shipments were refused entry. A small, separate 2023 retail survey of nine domestically acquired clam samples found eight below the PFOA detection limit. These were selected surveys, not prevalence estimates for all clams or all seafood. FDA follow-up results.
The FDA added eight processed-clam firms to an import alert in February 2025. Its current monitoring page says further bivalve sampling carried out in 2024 and 2025 remains under review. That supports attention to the affected source and actual regulatory findings; it does not justify labeling every shellfish product contaminated or every domestic product contaminant-free. Import-alert announcement, current monitoring status.
The same interpretation principle applies to a report of “arsenic”: total arsenic does not specify the inorganic fraction, and chemical forms have different toxicity. “Organic arsenic” describes chemical structure, not organic farming certification. A total measurement alone should not be treated as an equal amount of inorganic arsenic. FDA arsenic explanation.
The decision at the shelf
Use the seafood comparison to choose a palatable product, then check sodium per whole portion. Salmon remains an option. No specific alternative has been adopted.
My reported sardine label gives 210 mg sodium and 1.74 g total omega-3 for one drained 80 g can. Those are product-label facts, not contaminant measurements; the exact EPA/DHA split is still unverified. “In olive oil,” “wild caught,” “organic,” or a sourcing story does not supply a mercury assay. A new fish label should be recorded before replacing those figures in the log.
An unopened shelf-stable can is also different from an opened can or chilled fish. Under the current storage constraints, finishing the opened portion avoids depending on unreliable leftover storage. Histamine formation is another reason the supply chain and handling matter: it can occur in susceptible fish, including products that are later cooked or canned, and is not the same question as mercury. This does not establish that my fish caused any reaction. FDA scombrotoxin explanation.
Choose an enjoyable product and check sodium per portion. Specific recalls or measured sourcing problems can change that choice; an untested can gets no contaminant score.